Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04372277 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04372277 · ClinicalTrials.gov record · last posted 2020-05-04

Taltz in Combination With Enstilar for Psoriasis

Name: Taltz in Combination With Enstilar for Psoriasis — clinical trial record (NCT04372277)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorPsoriasis Treatment Center of Central New Jersey

Started2020-04-28

View on ClinicalTrials.gov ↗

Record status

This record was last updated May 4, 2020 (before its estimated March 1, 2021 completion). Its status may not reflect the trial's current state.

from the ClinicalTrials.gov record

Enstilar in combination with Taltz for plaque psoriasis.

Amendment record 1 amendment on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended once since 2020-04-29. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-03-14

Status change Recruiting→Completedv1

Trial Details

NCT Number	NCT04372277
Lead Sponsor	Psoriasis Treatment Center of Central New Jersey Collaborators: Eli Lilly and Company
Conditions	Psoriasis
Enrollment	25 participants
Start Date	2020-04-28
Primary Completion	2021-03-01 (estimated)
Study Completion	2021-03-30 (estimated)
Updated on ClinicalTrials.gov	2020-05-04